Sarcoidosis Treatment Approach

Initial Treatment and Assessment

The European Respiratory Society recommends oral prednisone at 20-40 mg daily for 3-6 months as the first-line treatment for symptomatic sarcoidosis nodules, with subsequent tapering to the lowest effective dose 1, 2, 3
Nearly half of sarcoidosis patients never require systemic treatment as the disease may resolve spontaneously, according to the European Respiratory Society 3
Treatment decisions should be based on three key factors: risk of mortality or permanent disability, significant impairment of quality of life, and presence of symptoms, as suggested by the European Respiratory Journal 4, 5

Initial therapy with prednisone 20-40 mg daily for 3-6 months is recommended, with dose reductions for patients with diabetes, psychosis, or osteoporosis, as advised by the European Respiratory Review 1, 2, 3
For patients with worsening quality of life but lower risk, consider initial low-to-medium dose glucocorticoid treatment (5-10 mg daily), as recommended by the European Respiratory Journal 5
For patients not at risk for morbidity/mortality and without significant quality of life impairment, no glucocorticoid treatment may be preferred due to high prevalence of adverse events, according to the European Respiratory Journal 5, 3

Add methotrexate (10-15 mg weekly) if there is disease progression despite adequate glucocorticoid treatment or unacceptable side effects from glucocorticoids, as recommended by the European Respiratory Review and European Respiratory Journal 1, 2, 4, 6
Methotrexate is the most widely studied and best-tolerated second-line agent, according to the European Respiratory Review 1, 3

Add infliximab for patients with continued disease despite glucocorticoids and second-line agents, as recommended by the European Respiratory Journal 6, 2, 4
Infliximab has multiple clinical trials supporting its use in various manifestations of sarcoidosis, according to the European Respiratory Review 1

Continue therapy for at least 3-6 months if there is improvement, and re-evaluate the need for continued successful treatment every 1-2 years, as advised by the European Respiratory Review and European Respiratory Journal 2, 3
At least half of patients started on glucocorticoids may still be on treatment 2 years later, according to the European Respiratory Review 2, 3

Prolonged use of even low doses of prednisone can lead to significant toxicity, including weight gain, steroid-induced complications, and reduced quality of life, as warned by the European Respiratory Review 1
Adding inhaled glucocorticoids to oral glucocorticoids does not provide significant benefits, according to the European Respiratory Journal 5